Merck & Co., Inc. (MRK) CEO Rob Davis on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/03/22
Merck expects to sell $5 billion to $6 billion of its new Covid treatment pill in 2022CNBC • 02/03/22
Merck, Ridgeback says COVID-19 pill molnupiravir shows antiviral activity against omicron variantMarket Watch • 01/28/22
Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro StudiesBusiness Wire • 01/28/22
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following SurgeryBusiness Wire • 01/27/22